Forteo

Shares of the micro-cap biotech Pfenex Inc (NYSE: PFNX), which pulled back ahead of the PDUFA date for its Forteo biosimilar PF708, were advancing Monday amid a positive outcome for the binary event. FDA Hurdle Crossed The FDA has approved its NDA for PF708 under the 505(b)(2) regulatory...

Pfenex Inc (NYSE: PFNX) has a key binary event coming up: mark your calendar for Oct. 7, when the FDA is scheduled to issue its verdict on the company's lead drug candidate. Through its production platform Pfenex Expression Technology, the biotech Pfenex engages in the development of high-value...

H.C. Wainwright & Co.'s Carol Ann Werther initiated Radius Health Inc (NASDAQ: RDUS) at Buy with a $55.00 price target. The company's lead product candidate is abaloparatide (ABL), which is currently under review in Europe and the United States. "We expect launches in 4Q16 and 1Q17," said...